A new window connecting medical oncologists and interventional oncologists

The article titled ‘Transarterial management of advanced lung cancer’ (1) introduces excellent clinical outcomes. It is a retrospective review of cases of patient who received very special treatments, such as super-selective arterial infusion chemotherapy and embolotherapy, and it is likely that the cohort included in this study were lucky cases showing good clinical results by chance. Hence, it is not adequate enough to call these findings as ‘evidence’. However, is it correct to ignore these results for not providing sufficient evidence?
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research